These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36229921)

  • 1. Trends in prescriptions of oral medications for psoriasis: A single-center retrospective study.
    Takano-Kawasaki S; Sato E; Yamaguchi K; Imafuku S
    J Dermatol; 2023 Jan; 50(1):82-88. PubMed ID: 36229921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
    Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
    J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug survival of apremilast in a real-world setting.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2019 Jul; 46(7):615-617. PubMed ID: 31180150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
    Mahrle G; Schulze HJ; Färber L; Weidinger G; Steigleder GK
    J Am Acad Dermatol; 1995 Jan; 32(1):78-88. PubMed ID: 7822521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the safety of apremilast for the treatment of plaque psoriasis.
    Shavit E; Shear NH
    Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
    [No Abstract]   [Full Text] [Related]  

  • 7. Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.
    James WA; Rosenberg AL; Wu JJ; Hsu S; Armstrong A; Wallace EB; Lee LW; Merola J; Schwartzman S; Gladman D; Liu C; Koo J; Hawkes JE; Reddy S; Prussick R; Yamauchi P; Lewitt M; Soung J; Weinberg J; Lebwohl M; Glick B; Kircik L; Desai S; Feldman SR; Zaino ML
    J Am Acad Dermatol; 2024 Aug; 91(2):251.e1-251.e11. PubMed ID: 38499181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
    Sbidian E; Billionnet C; Weill A; Maura G; Mezzarobba M
    Br J Dermatol; 2020 Mar; 182(3):690-697. PubMed ID: 31021438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable response to apremilast in a patient with refractory psoriasis verrucosa.
    Okazaki S; Osawa R; Nakajima H; Nakajima K; Sano S
    J Dermatol; 2019 Jun; 46(6):544-547. PubMed ID: 30957901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study.
    Pavia G; Gargiulo L; Cortese A; Valenti M; Sanna F; Borroni RG; Costanzo A; Narcisi A
    Dermatol Ther; 2022 Feb; 35(2):e15253. PubMed ID: 34877758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future oral systemic therapies for psoriasis.
    Kelly JB; Foley P; Strober BE
    Dermatol Clin; 2015 Jan; 33(1):91-109. PubMed ID: 25412786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
    Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
    Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
    J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessor-blinded, comparative study.
    Hassanandani T; Panda M; Jena AK; Raj C
    Indian J Dermatol Venereol Leprol; 2023; 89(2):213-220. PubMed ID: 35841363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T; Puig L
    Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.